Switching hemodialysis patients from sevelamer hydrochloride to bixalomer: A single-center, non-randomized analysis of efficacy and effects on gastrointestinal symptoms and metabolic acidosis

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Hatakeyama, Shingo ^a   Murasawa, Hiromi ^b   Narita, Takuma ^a   Oikawa, Masaaki ^a   Fujita, Naoki ^a   Iwamura, Hiromichi ^a   Mikami, Joutaro ^a   Kojima, Yuta ^a   Sato, Tendo ^a   Fukushi, Ken ^a   Ishibashi, Yusuke ^a   Hashimoto, Yasuhiro ^a   Koie, Takuya ^a   Saitoh, Hisao ^b   Funyu, Tomihisa ^b   Ohyama, Chikara ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b Oyokyo Kidney Research Institute   (Japan)

Author keywords

Bixalomer; Gastrointestinal disorder; Hemodialysis; Hyperphosphatemia; Metabolic acidosis

Indexed keywords

BIXALOMER; SEVELAMER;

ABDOMINAL DISCOMFORT; ADVERSE OUTCOME; ANION GAP; ARTICLE; BLOOD CHEMISTRY; BLOOD GAS ANALYSIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIGASTRIC FULLNESS; FECES COMPOSITION; FEMALE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; MALE; METABOLIC ACIDOSIS; NAUSEA; PATIENT SATISFACTION; PROSPECTIVE STUDY; SIDE EFFECT; STOMACH; STOMACH PAIN; TREATMENT RESPONSE;

ACIDOSIS; CHELATING AGENTS; DRUG SUBSTITUTION; FEMALE; GASTROINTESTINAL DISEASES; HEMODIALYSIS SOLUTIONS; HUMANS; HYPERPHOSPHATEMIA; MALE; MIDDLE AGED; POLYAMINES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 84885341531     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-222     Document Type: Article

References (17)

1. Hyperphosphatemia of chronic kidney disease. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R, Kidney Int 2008 74 2 148 157 10.1038/ki.2008.130 18449174 (Pubitemid 351915080)
2. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, et al. N Engl J Med 2000 342 20 1478 1483 10.1056/NEJM200005183422003 10816185 (Pubitemid 30318271)
3. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. National Kidney Foundation, Am J Kidney Dis 2003 42 1 S201 14520607
4. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF, Am J Kidney Dis 2009 54 4 619 637 10.1053/j.ajkd.2009.06.004 19692157
5. Sevelamer worsens metabolic acidosis in hemodialysis patients. De Santo NG, Frangiosa A, Anastasio P, Marino A, Correale G, Perna A, Di Stazio E, Stellato D, Santoro D, Di Meglio E, et al. J Nephrol 2006 19 Suppl 9 108 S114 16736432
6. Progress in the management of phosphorus in chronic kidney disease. Kurihara S, Kidney Metab Bone Dis 2004 17 4 363 370
7. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Bommer J, Locatelli F, Satayathum S, Keen ML, Goodkin DA, Saito A, Akiba T, Port FK, Young EW, Am J Kidney Dis 2004 44 4 661 671 15384017 (Pubitemid 39237610)
8. A phase III, sevelamer HCI-controlled study of bixalomer in chronic kidney disease (CKD) patients on hemodialysis with hyperphosphatemia American society of nephrology kidney week 2011 abstract FR-PO1669. Akizawa TO, Akizawa TOH, Kameoka C, J Am Soc Nephrol 2011 22 501A
9. Studies on the physicochemical characteristic of polymer mixed with water at the ratio of dosage and administration given to patients. Kakuta HT, Kakuta HTK, Sakaguchi H, Jpn J Clin Dial 2012 28 115 120
10. Toxicity and response criteria of the Eastern cooperative oncology group. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP, Am J Clin Oncol 1982 5 6 649 655 10.1097/00000421-198212000-00014 7165009 (Pubitemid 13149996)
11. Abdominal symptom-related QOL in individuals visiting an outpatient clinic and those attending an annual health check. Kakuta E, Yamashita N, Katsube T, Kushiyama Y, Suetsugu H, Furuta K, Kinoshita Y, Intern Med 2011 50 15 1517 1522 10.2169/internalmedicine.50.5390 21804275
12. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. O'Donnell LJ, Virjee J, Heaton KW, BMJ Clin Res 1990 300 6722 439 440 10.1136/bmj.300.6722.439 (Pubitemid 20069266)
13. Stool form scale as a useful guide to intestinal transit time. Lewis SJ, Heaton KW, Scand J Gastroenterol 1997 32 9 920 924 10.3109/00365529709011203 9299672 (Pubitemid 27382038)
14. Gahart BL, Nazareno AR, Intravenous medications: a handbook for nurses and health professionals St. Louis, Mo: Mosby Elsevier 24 2008
15. Pharmacological and clinical profile of bixalomer (Kiklin((R)) capsules): a new therapeutic agent for hyperphosphatemia. Taniguchi K, Kakuta H, Tomura Y, Kaku S, Uchida W, Nihon Yakurigaku Zasshi 2013 141 6 333 337 10.1254/fpj.141.333 23749074
16. Long-term treatment of hyperphosphatemia with bixalomer in Japanese hemodialysis patients. Akizawa T, Kameoka C, Kaneko Y, Kawasaki S, Ther Apher Dial 2013 doi:10.1111/1744-9987.12023
17. Prospective study on the effects of sevelamer hydrochloride and lanthanum carbonate on acid-base balance. Matsushita KTH, Nitta K, Tago K, Jpn Soc Dial Ther J 2010 43 763 768 10.4009/jsdt.43.763